Norway's govt must invest in medical industry, says LMI

Norway must institute broad-based government investment in the medical industry that considers the value chain of the entire industry, from research to patient ("the sixth investment area"), says the country’s research-based pharmaceutical industry trade group the LMI in a policy statement released last week.

Biomedicine can be an important growth industry for Norway, and a means of responding to the great social challenges faced in the years ahead. New, innovative medicinal products that are found to be cost-effective for society must be introduced and made available to patients, the association contends.

There is a need for incentives to encourage greater commercialization of medical research and cooperation on research and business development between the industry, the regional health authorities, the universities and the TTOs.